Company Filing History:
Years Active: 2018
Title: John Orczyk: Innovator in Cancer Detection Technologies
Introduction
John Orczyk is a notable inventor based in West Lafayette, Indiana, recognized for his contributions to cancer detection technologies. He holds a patent that focuses on innovative methods for identifying and quantifying ENOX2 transcript variants, which serve as indicators of cancer presence in blood serum and other body fluids.
Latest Patents
Orczyk's patent, titled "Methods and compositions for identification and quantification of ENOX2 transcript variants as indications of cancer presence in blood serum and other body fluids based on gold or silver nanoparticle formation," presents a semi-quantitative method for detecting ENOX2 transcript variants. This method involves several steps, including electrophoretically separating proteins from a concentrated blood, serum, or plasma sample, transferring these proteins to a substrate, and measuring the conversion of ionic silver or gold to colloidal forms. The detection is achieved through light scattering from anti-ENOX2 antibody binding spots on the substrate, with each spot indicating the presence of an ENOX2 transcript variant. This invention also lays the groundwork for a point-of-care test that utilizes colloidal gold or silver complexes with ENOX2 for rapid cancer detection.
Career Highlights
John Orczyk is affiliated with Mor-nuco Enterprises, Inc., where he continues to develop and refine his innovative technologies. His work is pivotal in advancing the field of cancer diagnostics, providing new tools for early detection and treatment.
Collaborations
Orczyk collaborates with D James Morre, enhancing the research and development efforts within his company. Their partnership focuses on leveraging their combined expertise to push the boundaries of cancer detection technologies.
Conclusion
John Orczyk's innovative work in cancer detection through the identification of ENOX2 transcript variants represents a significant advancement in medical diagnostics. His contributions are vital for improving early cancer detection methods, ultimately benefiting patient care and treatment outcomes.